Arvinas, Inc. ARVN

What this company does

As of December 31, 2025, the company had approximately 246 full-time employees, of whom 188 were engaged in research and development activities and approximately 50 in general and administrative activities. It is progressing five product candidates through clinical development: ARV-102, targeting the LRRK2 protein for neurodegenerative diseases including Parkinson's disease and progressive supranuclear palsy; ARV-806, targeting KRAS-G12D for pancreatic, colorectal and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for locally advanced or metastatic ER+/HER2- breast cancer. The company does not own or operate manufacturing facilities and relies on third-party contract manufacturing and contract development and manufacturing organizations for drug substance, finished drug product, and preclinical compound synthesis. In July 2021, the company entered into a collaboration agreement with Pfizer under which it granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing its compound vepdegestrant, and received an upfront, non-refundable payment of $650 million.

Written from the business description in ARVINAS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.